JP2008515954A - ＶＬＰおよびアミロイドβペプチドを含む組成物 - Google Patents

ＶＬＰおよびアミロイドβペプチドを含む組成物 Download PDF

Info

Publication number
JP2008515954A
JP2008515954A JP2007536128A JP2007536128A JP2008515954A JP 2008515954 A JP2008515954 A JP 2008515954A JP 2007536128 A JP2007536128 A JP 2007536128A JP 2007536128 A JP2007536128 A JP 2007536128A JP 2008515954 A JP2008515954 A JP 2008515954A
Authority
JP
Japan
Prior art keywords
peptide
fragment
construct
dementia
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007536128A
Other languages
English (en)
Japanese (ja)
Inventor
アナ・グラーフ
マティアス・シュタウフェンビール
トーマス・ブレットラー
パオロ・パガネッティ
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33523293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008515954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2008515954A publication Critical patent/JP2008515954A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007536128A 2004-11-05 2005-11-03 ＶＬＰおよびアミロイドβペプチドを含む組成物 Withdrawn JP2008515954A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424563A GB0424563D0 (en) 2004-11-05 2004-11-05 Organic compounds
PCT/EP2005/011788 WO2006048295A1 (en) 2004-11-05 2005-11-03 Composition compri sing vlp and amyloid - beta peptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011102847A Division JP2011157395A (ja) 2004-11-05 2011-05-02 ＶＬＰおよびアミロイドβペプチドを含む組成物

Publications (1)

Publication Number Publication Date
JP2008515954A true JP2008515954A (ja) 2008-05-15

Family

ID=33523293

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007536128A Withdrawn JP2008515954A (ja) 2004-11-05 2005-11-03 ＶＬＰおよびアミロイドβペプチドを含む組成物
JP2011102847A Pending JP2011157395A (ja) 2004-11-05 2011-05-02 ＶＬＰおよびアミロイドβペプチドを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011102847A Pending JP2011157395A (ja) 2004-11-05 2011-05-02 ＶＬＰおよびアミロイドβペプチドを含む組成物

Country Status (25)

Country Link
US (4) US7867499B2 (https=)
EP (2) EP2286830A3 (https=)
JP (2) JP2008515954A (https=)
KR (1) KR20070073882A (https=)
CN (1) CN101048174A (https=)
AR (1) AR054092A1 (https=)
AU (2) AU2005300692A1 (https=)
BR (1) BRPI0517682A (https=)
CA (1) CA2581300A1 (https=)
EC (1) ECSP077415A (https=)
GB (1) GB0424563D0 (https=)
GT (1) GT200500313A (https=)
IL (1) IL182692A (https=)
MA (1) MA29020B1 (https=)
MX (1) MX2007005430A (https=)
MY (1) MY148584A (https=)
NO (1) NO20072743L (https=)
NZ (1) NZ583688A (https=)
PE (1) PE20061047A1 (https=)
RU (1) RU2415677C2 (https=)
SG (1) SG170646A1 (https=)
TN (1) TNSN07166A1 (https=)
TW (1) TWI380825B (https=)
WO (1) WO2006048295A1 (https=)
ZA (1) ZA200702369B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523682A (ja) * 2010-03-29 2013-06-17 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
JP2004522736A (ja) * 2001-01-19 2004-07-29 サイトス バイオテクノロジー アーゲー 分子抗原アレイ

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0038154B1 (en) 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01501064A (ja) 1986-09-22 1989-04-13 エモリ　ユニバーシティ ワクチンとその製法
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5142726A (en) * 1991-04-03 1992-09-01 Mann Robert F Adjustable bristle length toothbrush
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US6180771B1 (en) 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
JPH09202735A (ja) 1996-01-25 1997-08-05 Nof Corp リポソーム型アレルギー治療薬
US5786161A (en) 1996-06-06 1998-07-28 Miltenyi Biotec. Gmbh Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity
SE9604815D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
WO1999040934A1 (en) 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
EA004497B1 (ru) 1998-12-04 2004-04-29 Байоджен, Инк. Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
CN1520423A (zh) 1999-02-25 2004-08-11 ʷ��˿�������ȳ�ķ���޹�˾ 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001053457A2 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US8519005B2 (en) * 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219459A1 (en) 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
MXPA04011247A (es) 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.
WO2004016262A1 (ja) 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004522736A (ja) * 2001-01-19 2004-07-29 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010030028; ＧＯＬＤＥ，　Ｔ．Ｅ．: 'Ａｌｚｈｅｉｍｅｒ　ｄｉｓｅａｓｅ　ｔｈｅｒａｐｙ：　Ｃａｎ　ｔｈｅ　ａｍｙｌｏｉｄ　ｃａｓｃａｄｅ　ｂｅ　ｈａｌｔｅｄ？' Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｉｎｖｅｓｔｉｇａｔｉｏｎ Ｖｏｌ．１１１，　Ｎｏ．１, 200301, ｐ．１１-１８ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523682A (ja) * 2010-03-29 2013-06-17 ノバルティス アーゲー ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物

Also Published As

Publication number Publication date
JP2011157395A (ja) 2011-08-18
US20090060899A1 (en) 2009-03-05
ECSP077415A (es) 2007-05-30
AU2010200410B2 (en) 2011-10-13
EP2286830A3 (en) 2011-03-30
TW200621288A (en) 2006-07-01
US20130252889A1 (en) 2013-09-26
IL182692A0 (en) 2007-09-20
TNSN07166A1 (en) 2008-11-21
US8460676B2 (en) 2013-06-11
US7867499B2 (en) 2011-01-11
KR20070073882A (ko) 2007-07-10
RU2007120689A (ru) 2008-12-20
BRPI0517682A (pt) 2008-10-14
CN101048174A (zh) 2007-10-03
RU2415677C2 (ru) 2011-04-10
GB0424563D0 (en) 2004-12-08
CA2581300A1 (en) 2006-05-11
US20110086036A1 (en) 2011-04-14
GT200500313A (es) 2006-12-18
AR054092A1 (es) 2007-06-06
AU2010200410A1 (en) 2010-02-25
US20140079730A1 (en) 2014-03-20
NO20072743L (no) 2007-05-30
AU2005300692A1 (en) 2006-05-11
MA29020B1 (fr) 2007-11-01
NZ583688A (en) 2011-10-28
EP1812050A1 (en) 2007-08-01
PE20061047A1 (es) 2006-11-07
IL182692A (en) 2010-12-30
MY148584A (en) 2013-04-30
MX2007005430A (es) 2007-05-18
WO2006048295A1 (en) 2006-05-11
SG170646A1 (en) 2011-05-30
ZA200702369B (en) 2008-09-25
US8617566B2 (en) 2013-12-31
EP2286830A2 (en) 2011-02-23
TWI380825B (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
JP6088422B2 (ja) ウイルス様粒子に結合しているアミロイドベータ１−６ペプチドおよびアジュバントを含む組成物
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
US8617566B2 (en) Composition comprising VLP and amyloid beta peptide
AU2011253800B2 (en) Composition comprising VLP and amyloid-beta peptide
HK1150961A (en) Composition comprising vlp and amyloid-beta peptide
AU2015254663A1 (en) Treatment and prevention of Alzheimer's Disease (AD)

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120327

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140718

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140723

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140820